UPDATE 1-Novo Holdings to buy Catalent for $11.5 billion to expand Wegovy capacity
(Adds details throughout)
Feb 5 (Reuters) - Novo Holdings, the holding company of Novo Nordisk, will buy contract drugmaker Catalent in an all-cash transaction worth $11.5 billion in equity value to expand its capacity for popular weight-loss drug Wegovy, the companies said on Monday.
Under the deal, Novo Holdings will buy all outstanding shares of Catalent for $63.50 per share in cash, a premium of 16.5% to Catalent's last trading price.
Novo will acquire three fill-finish sites from Catalent under the deal, which is expected to gradually help increase Novo's filling capacity from 2026 onwards.
The Danish company will also take on Catalent's debt, taking the total enterprise value of the deal to $16.5 billion. (Reporting by Leroy Leo in Bengaluru; Editing by Dhanya Ann Thoppil and Shounak Dasgupta)
